Replies to post #111141 on Biotech Values

[jq1234]

I agree with you completely. Nothing new there. In light of their analysis, $15 target doesn't make any sense:

A duopoly with Sanofi on the $1.8bn US market of Lovenox. We see
MNTA having a multi-year duopoly with Sanofi. However, if other
competitors enter the market, MNTA’s earnings power would dramatically
decline (from $3 per share to $0.20 per share, in our estimation). While we
see low probability of a competitor approval in the next few years, we see
the overhang only lifting with time, capping upside. High probability of
generic Copaxone approval. MNTA needs to overcome two hurdles: 1)
FDA approval – we are bullish given generic Lovenox approval and 2)
Teva’s Copaxone patents – trial in 2011/12. We expect the market to give
little credit for generic Copaxone until the litigation outcome is known.